Информация предназначена только для профессионалов в области здравоохранения.
Вы можете зайти как пользователь социальных сетей
ФГБУ НИИ фармакологии им. В.В.Закусова Российской академии медицинских наук, Москва
Список исп. литературыСкрыть список
1. Harris EC, Barraclough B. Suicide as an outcome for mental disorders. A meta-analysis. Br J Psychiatry 1997; 170 (3): 205–28.
2. Craddock N, Jones I. Genetics of bipolar disorder. J Med Genet 1999; 36 (8): 585–94.
3. Vehmanen L, Kaprio J, Loennqvist J. Twin studies on concordance for bipolar disorder. Psychiatr Fenn 1995; 26: 107–16.
4. Rihmer A et al. Affective temperaments, as measured by TEMPS-A, among nonviolent suicide attempters. J Affect Disord 2009; 116 (1–2): 18–22.
5. Roy A, Sarchiopone M, Carli V. Gene-environment interaction and suicidal behavior. J Psychiatr Pract 2009; 15 (4): 282–8.
6. Gonda X et al. Suicidal behavior in bipolar disorder: epidemiology, characteristics and major risk factors. J Affect Disord 2012; 143 (1–3): 16–26.
7. Dalén P et al. 10-Hydroxylation of nortriptyline in white persons with 0, 1, 2, 3, and 13 functional CYP2D6 genes. Clin Pharmacol Ther 1998; 63: 444–52.
8. Kawanishi C et al. Increased incidence of CYP2D6 gene duplication in patients with persistent mood disorders: ultrarapid metabolism of antidepressants as a cause of nonresponse. A pilot study. Eur J Clin Pharmacol 2004; 59: 803–7.
9. Zackrisson AL, Lindblom B, Ahlner J. High frequency of occurrence of CYP2D6 gene duplication/multiduplication indicating ultrarapid metabolism among suicide cases. Clin Pharmacol Ther 2010; 88: 354–9.
10. Bertilsson L et al. Debrisoquine hydroxylation polymorphism and personality. Lancet 1989; 1 (8637): 555.
11. Mahmood T, Silverstone T. Serotonin and bipolar disorder. J Affect Disord 2001; 66: 1–11.
12. Young LT et al. Reduced brain 5-HT and elevated NE turnover and metabolites in bipolar affective disorder. Biol Psychiatry 1994; 35: 121–7.
13. Leake A et al. Studies on the serotonin uptake binding site in major depressive disorder and control post-mortem brain: neurochemical and clinical correlates. Psychiatry Res 1991; 39: 155–65.
14. O’Connell RA et al. Single-photon emission computed tomography of the brain in acute mania and schizophrenia. J Neuroimaging 1995; 5: 101–4.
15. Gyulai L et al. I-123 iofetamine single-photon computed emission tomography in rapid cycling bipolar disorder: a clinical study. Biol Psychiatry 1997; 41: 152–61.
16. Asberg M et al. CSF monoamine metabolites in melancholia. Acta Psychiatr Scand 1984; 69: 201–19.
17. Swann AC et al. CSF monoamine metabolites in mania. Am J Psychiatry 1983; 140: 396–400.
18. Ellis PM et al. Platelet tritiated imipramine binding in patients suffering from mania. J Affect Disord 1991; 22: 105–10.
19. Meagher JB et al. Changes in platelet 5-hydroxytryptamine uptake in mania. J Affect Disord 1990; 19: 191–6.
20. Lewis DA, McChesney C. Tritiated imipramine binding distinguishes among subtypes of depression. Arch Gen Psychiatry 1985; 42: 485–8.
21. Masoliver E et al. Serotonin transporter linked promoter (polymorphism) in the serotonin transporter gene may be associated with antidepressant-induced mania in bipolar disorder. Psychiatr Genet 2006; 16: 25–9.
22. Frank B et al. Investigation of the human serotonin receptor gene HTR3B in bipolar affective and schizophrenic patients. Am J Med Genet B Neuropsychiatr Genet 2004; 131B: 1–5.
23. Gutierrez B et al. Allelic association analysis of the 5-HT2C receptor gene in bipolar affective disorder. Neurosci Lett 1996; 212: 65–7.
24. Lerer B et al. Variability of 5-HT2C receptor cys23ser polymorphism among European populations and vulnerability to affective disorder. Mol Psychiatry 2001; 6 (5): 579–85.
25. Bellivier F et al. Association between the tryptophan hydroxylase gene and manic-depressive illness. Arch Gen Psychiatry 1998; 55: 33–7.
26. Porcelli S, Fabbri C, Serretti A. Meta-analysis of serotonin transporter gene promoter polymorphism (5-HTTLPR) association with antidepressant efficacy. Eur Neuropsychopharmacol 2012; 22 (4): 239–58.
27. Serretti A et al. Meta-analysis of serotonin transporter gene promoter polymorphism (5-HTTLPR) association with selective serotonin reuptake inhibitor efficacy in depressed patients. Mol Psychiatry 2007; 12: 247–57.
28. Keers R, Aitchison KJ. Pharmacogenetics of antidepressant response. Expert Rev Neurother 2011; 11 (1): 101–25.
29. Joyce PR et al. Age-dependent antidepressant pharmacogenomics: polymorphisms of the serotonin transporter and G protein b3 subunit as predictors of response to fluoxetine and nortriptyline. Int J Neuropsychopharmacol 2003; 6: 339–46.
30. Putzhammer A et al. Evidence of a role for the 5-HTTLPR genotype in the modulation of motor response to antidepressant treatment. Psychopharmacology (Berl) 2005; 178: 303–8.
31. Perlis RH et al. Serotonin transporter polymorphisms and adverse effects with fluoxetine treatment. Biol Psychiatry 2003; 54: 879–83.
32. Mundo E et al. The role of serotonin transporter protein gene in antidepressant-induced mania in bipolar disorder: preliminary findings. Arch Gen Psychiatry 2001; 58 (6): 539–44.
33. Villafuerte SM et al. SSRI response in depression may be influenced by SNPs in HTR1B and HTR1A. Psychiatr Genet 2009; 19: 281–91.
34. Noro M et al. 5HT1A and 5HT2A receptor genes in treatment response phenotypes in major depressive disorder. Int Clin Psychopharmacol 2010; 25: 228–31.
35. Illi A et al. 5-HTR1A, 5-HTR2A, 5-HTR6, TPH1 and TPH2 polymorphisms and major depression. Neuroreport 2009; 20: 1125–8.
36. Peters EJ et al. Investigation of serotonin-related genes in antidepressant response. Mol Psychiatry 2004; 9: 879–89.
37. McMahon FJ et al. Variation in the gene encoding the serotonin 2A receptor is associated with outcome of antidepressant treatment. Am J Hum Genet 2006; 78: 804–14.
38. Viikki M et al. Interaction between two HTR2A polymorphisms and gender is associated with treatment response in MDD. Neurosci Lett 2011; 501: 20–4.
39. Thomas KLH, Ellingrod VL. Pharmacogenetics of selective serotonin reuptake inhibitors and associated adverse drug reactions. Pharmacotherapy 2009; 29 (7): 822–31.
40. Wang H-C et al. TPH1 is associated with major depressive disorder but not with SSRI/SNRI response in Taiwanese patients. Psychopharmacology (Berl) 2011; 213: 773–9.
41. Ham B-J et al. Association between the tryptophan hydroxylase-1 gene A218C polymorphism and citalopram antidepressant response in a Korean population. Prog Neuropsychopharmacol Biol Psychiatry 2007; 31: 104–7.
42. Serretti A. Pharmacogenomics of psychotropic drugs. Pharmacogenomics 2011; 12 (11): 1509–10.
43. Tsai SJ et al. Tryptophan hydroxylase 2 gene is associated with major depression and antidepressant treatment response. Prog Neuropsychopharmacology Biol Psychiatry 2009.
44. McHugh PC et al. A polymorphism of the GTP-cyclohydrolase I feedback regulator gene alters transcriptional activity and may affect response to SSRI antidepressants. Pharmacogenomics J 2011; 11: 207–13.
45. Yu YW et al. Association study of a monoamine oxidase a gene promoter polymorphism with major depressive disorder and antidepressant response. Neuropsychopharmacology 2005; 30: 1719–23.
46. Arias B et al. Analysis of COMT gene (Val 158 Met polymorphism) in the clinical response to SSRIs in depressive patients of European origin. J Affect Disord 2006; 90: 251–6.
47. Benedetti F et al. Effect of catechol-O-methyltransferase Val(108/158)Met polymorphism on antidepressant efficacy of fluvoxamine. Eur Psychiatry 2010; 25: 476–8.
48. Snyder K et al. Catechol O-methyltransferase pharmacogenomics and selective serotonin reuptake inhibitor response. Pharmacogenomics J 2012; 12: 78–85.
49. Chou JC-Y, Fazzio L. Maintenance treatment of bipolar disorder: Applying research to clinical practice. J Psychiatr Pract 2006; 12 (5): 283–99.
50. Zou Y-F et al. Association of brain-derived neurotrophic factor genetic Val66Met polymorphism with severity of depression, efficacy of fluoxetine and its side effects in Chinese major depressive patients. Neuropsychobiology 2010; 61 (2): 71–8.
51. Licinio J et al. Association of a corticotropin-releasing hormone receptor 1 haplotype and antidepressant treatment response in Mexican-Americans. Mol Psychiatry 2004; 9 (12): 1075–82.
52. Uher R et al. Genetic predictors of response to antidepressants in the GENDEP project. Pharmacogenomics J 2009; 9 (4): 225–33.
53. Esposito K et al. Phosphodiesterase genes and antidepressant treatment response: a review. Ann Med 2008; 41 (3): 177–85.
54. Li X et al. In vivo regulation of glycogen synthase kinase-3b (GSK3) by serotonergic activity in mouse brain. Neuropsychopharmacology 2004; 29 (8): 1426–31.
55. Horstmann S et al. Polymorphisms in GRIK4, HTR2A, and FKBP5 show interactive effects in predicting remission to antidepressant treatment. Neuropsychopharmacology 2010; 35 (3): 727–40.
56. Serretti A et al. A preliminary investigation of the influence of CREB1 gene on treatment resistance in major depression. J Affect Disord 2011; 128 (1–2): 56–63.
57. Hedenmalm K et al. Risk factors for extrapyramidal symptoms during treatment with selective serotonin reuptake inhibitors, including cytochrome P-450 enzyme, and serotonin and dopamine transporter and receptor polymorphisms. J Clin Psychopharmacol 2006; 26 (2): 192–7.
58. Laje G et al. Genetic markers of suicidal ideation emerging during citalopram treatment of major depression. Am J Psychiatry 2007; 164 (10): 1530–8.
59. Perlis RH et al. Association between treatment-emergent suicidal ideation with citalopram and polymorphisms near cyclic adenosine monophosphate response element binding protein in the STAR*D study. Arch Gen Psychiatry 2007; 64 (6): 689–97.
60. Cipriani A et al. Lithium in the prevention of suicidal behavior and all-cause mortality in patients with mood disorders: a systematic review of randomized trials. Am J Psychiatry 2005; 162 (10): 1805–19.
61. Baldessarini RJ et al. Decreased risk of suicides and attempts during long-term lithium treatment: a meta-analytic review. Bipolar Disord 2006; 8 (5 Pt 2): 625–39.
62. Yerevanian BI, Choi YM. Impact of psychotropic drugs on suicide and suicidal behaviors. Bipolar Disord 2013; 15 (5): 594–621.
63. Cipriani A et al. Lithium in the prevention of suicide in mood disorders: updated systematic review and meta-analysis. BMJ 2013; 346: f3646.
64. Tondo L et al. Lithium treatment and risk of suicidal behavior in bipolar disorder patients. J Clin Psychiatry 1998; 59 (8): 405–14.
65. Lenox RH, Wang L. Molecular basis of lithium action: integration of lithium-responsive signaling and gene expression networks. Mol Psychiatry 2003; 8 (2): 135–44.
66. Serretti A, Drago A, De Ronchi D. Lithium pharmacodynamics and pharmacogenetics: focus on inositol mono phosphatase (IMPase), inositol poliphosphatase (IPPase) and glycogen sinthase kinase 3 beta (GSK-3b). Curr Med Chem 2009; 16 (15): 1917–48.
67. Jiménez E et al. Genetic variability at IMPA2, INPP1 and GSK3β increases the risk of suicidal behavior in bipolar patients. Eur Neuropsychopharmacol 2013; 23 (11): 1452–62.
68. Coryell W, Schlesser M. The dexamethasone suppression test and suicide prediction. Am J Psychiatry 2001; 158 (5): 748–53.
69. Pompili M et al. The hypothalamic-pituitary-adrenal axis and serotonin abnormalities: a selective overview for the implications of suicide prevention. Eur Arch Psychiatry Clin Neurosci 2010; 260 (8): 583–600.
70. Carballo JJ et al. Family history of suicidal behavior and early traumatic experiences: additive effect on suicidality and course of bipolar illness? J Affect Disord 2008; 109 (1–2): 57–63.
71. De Luca V, Tharmalingam S, Kennedy JL. Association study between the corticotropin-releasing hormone receptor 2 gene and suicidality in bipolar disorder. Eur Psychiatry 2007; 22 (5): 282–7.
72. Wasserman D et al. The CRHR1 gene: a marker for suicidality in depressed males exposed to low stress. Genes Brain Behav 2008; 7 (1): 14–9.
73. Roy A et al. Two HPA axis genes, CRHBP and FKBP5, interact with childhood trauma to increase the risk for suicidal behavior. J Psychiatr Res 2012; 46 (1): 72–9.
74. Willour VL et al. Family-based association of FKBP5 in bipolar disorder. Mol Psychiatry 2009; 14 (3): 261–8.
75. Turecki G. et al. Mapping susceptibility genes for bipolar disorder: a pharmacogenetic approach based on excellent response to lithium. Mol Psychiatry 2001; 6 (5): 570–8.
76. Squassina A et al. Evidence for association of an ACCN1 gene variant with response to lithium treatment in Sardinian patients with bipolar disorder. Pharmacogenomics 2011; 12 (11): 1559–69.
77. McCarthy MJ, Leckband SG, Kelsoe JR. Pharmacogenetics of lithium response in bipolar disorder. Pharmacogenomics 2010; 11 (10): 1439–65.
78. Perlis RH et al. A genomewide association study of response to lithium for prevention of recurrence in bipolar disorder. Am J Psychiatry 2009; 166 (6): 718–25.
79. Mparmpakas D et al. Placental DEPTOR as a stress sensor during pregnancy. Clin Sci (Lond) 2012; 122 (7): 349–59.
80. Tsai L-K et al. The mood stabilizers valproic acid and lithium enhance mesenchymal stem cell migration via distinct mechanisms. Neuropsychopharmacology 2010; 35 (11): 2225–37.
81. Hui W et al. Lithium protects cartilage from cytokine-mediated degradation by reducing collagen-degrading MMP production via inhibition of the P38 mitogen-activated protein kinase pathway. Rheumatology (Oxford) 2010; 49 (11): 2043–53.
82. Fu Y et al. A potential strategy for high-grade gliomas: combination treatment with lithium chloride and BmK CT. Biotechnol Lett 2012; 34 (1): 9–17.
83. Nadri C et al. Elevated urinary ADAM12 protein levels in lithium-treated bipolar patients. J Neural Transm 2007; 114 (4): 473–7.
84. Lee KW et al. Genome wide association studies (GWAS) and copy number variation (CNV) studies of the major psychoses: what have we learnt? Neurosci Biobehav Rev 2012; 36 (1): 556–71.